Search

Contribution deals with current key problems in measurement of some important bone markers. Namely is referred on the parathormon (PTH), bone turnover markers (BTM) and on the FGF-23 and sclerostin as markers of bone and mineral disorders in near future. Main problems are introduced. Stability, kind of samples, and choice of suitable method for routine analysis of field clinical laboratories in the case of PTH. Strong dependency of reference intervals for BTM on the used method. region, age, sex. Necessity of using the harmonized measurement units for S-CTx and S-P1NP results. Lack of modern, fast and comparable methodology for FGF-23 and sclerostine measurement. [ABSTRACT FROM AUTHOR]

Metabolic bone disease in chronic kidney disease and end-stage renal failure represents one of the most severe clinical complication in kidney patients, namely those on maintenance dialysis. Traditionally, bone changes are induced by secondary hyperparathyroidism. The CKD-MBD concept reflects the link between bone and cardiovascular disease in these patients. Studies documented also other bone pathological pathways in renal patients, such as osteoporosis, as in kidney and dialysis patients its risk factors are present as well as in general population. Resulting bone disease in renal disease and failure is far more complex than previously seen. However, the secondary hyperparathyroidism still represents the main pathological pathway.